查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088913

品牌學名藥市場：按劑型、治療領域、應用和分銷管道分類－2026-2032年全球市場預測

Branded Generics Market by Dosage Form, Therapeutic Area, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，品牌學名藥市場將成長至 5,852.4 億美元，複合年成長率為 6.29%。

主要市場統計數據
基準年 2025 3818.1億美元
預計年份：2026年 4051.4億美元
預測年份 2032 5852.4億美元
複合年成長率 (%) 6.29%

品牌非專利是指專利已過期、以獨特品牌名稱銷售的藥品。它們不僅具備學名藥的成本優勢，還擁有品牌帶來的信譽度、差異化包裝、醫生熟悉度和患者依從性支持。在許多市場，品牌仿製學名藥佔據著介於品牌藥和非品牌學名藥之間的重要地位，尤其是在那些處方決策受臨床可靠性、藥房供應情況、感知品質和供應穩定性影響的市場，這種趨勢更為明顯。

需求成長的促進因素包括專利到期、人口老化、慢性病盛行率上升、支付方為降低藥品支出所施加的壓力。來自包括美國食品藥物管理局（FDA）和世界衛生組織（WHO）在內的公共衛生組織的檢驗資訊來源一致強調，學名藥在改善藥品可及性和降低藥品成本方面發揮核心作用。同時，品牌學名藥在新興市場仍扮演著尤為重要的角色，因為在這些市場，品牌聲譽、監管合規性和品質保證是消費者購買學名藥的重要促進因素。

品牌學名藥市場的變革性變化

品牌非專利市場正從以銷售主導的擴張模式轉向以實證醫學和品質為導向的競爭模式。各國政府正在加強藥品定價監管，擴大參考定價範圍，推動學名藥的普及，並透過集中採購降低藥品成本，迫使生產商透過可靠性、廣泛的治療範圍和差異化的服務模式來證明自身的價值。

人工智慧對品牌非專利的累積影響

人工智慧 (AI) 正在加速品牌學名藥。

關於品牌非專利的關鍵區域性見解

亞太地區仍然是品牌學名藥的主要成長引擎，這得益於印度和中國的龐大生產規模、日本對學名藥的優惠報銷政策以及東南亞不斷擴大的醫療保險覆蓋範圍。該地區受益於大規模的患者群體、日益成長的慢性病治療需求以及旨在提高藥品可及性的政策舉措，同時監管機構也在不斷提高對藥品品質、生物等效性和安全性監測的要求。

戰略品牌非專利市場的關鍵群體洞察

在東協市場，監管協調、醫療保險覆蓋範圍擴大以及私人藥房網路的發展，正在改善不同收入水平和醫療環境下的消費者獲得品牌非專利的途徑，使其更具吸引力。在海灣合作理事會（GCC）國家，在地化、簡化的競標流程和藥品安全策略正在推進，為擁有區域夥伴關係關係、穩健的供應鏈和統一監管文件的合規生產商創造了機會。

針對特定國家/地區首選品牌非專利市場的關鍵洞察

美國在學名藥使用方面處於領先地位，這得益於FDA的監管、保險公司的處方藥清單以及強大的零售藥房網路。在加拿大，重點在於公共和私人醫保報銷規定、省級處方藥清單管理以及經濟實惠的用藥途徑。墨西哥和巴西由於人口眾多、慢性病負擔沉重、藥房管道不斷擴展以及監管能力的提升（尤其注重安全性、品質和生物等效性），對品牌學名藥的需求日益成長。

為行業領導者提供的實用建議

產業領導者應優先考慮那些慢性病負擔沉重、生物等效性已得到證實、供應穩定且專利保護期即將到期的市場，並以此為重點建立品牌非專利產品組合。商業策略應結合醫生教育、藥房合作、支持患者依從性的工具以及本地化的品牌推廣，以傳達品質、可及性和持續性，同時避免過分強調臨床差異。

調查方法

本執行摘要基於一套系統的調查方法，該方法結合了二手資料研究、監管審查、政策評估、市場三角驗證和專家解讀。公開檢驗的資訊來源包括監管指南、各國藥品監管機構、世界衛生組織基本藥物框架、美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）的資源、經合組織（OECD）的健康指標，以及來自公共和學術機構的權威藥品政策和取得文獻。

結論

品牌學名藥在全球藥品可及性方面繼續發揮核心作用，因為它們兼顧了價格可負擔性、治療熟悉度和品牌信任度。隨著醫療系統尋求控制成本，而患者、藥劑師和處方醫生繼續優先考慮可靠的品質、可及性和治療的連續性，品牌學名藥的重要性日益凸顯。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 品牌學名藥市場：依劑型分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 液體
    • 暫停
    • 糖漿
  • 片劑和膠囊
    • 緩釋製劑
    • 速釋製劑
  • 外用製劑
    • 奶油
    • 凝膠
    • 軟膏

第8章 品牌學名藥市場：依治療領域分類

  • 抗感染藥物
    • 抗生素
    • 抗真菌藥物
    • 抗病毒藥物
  • 心血管系統
    • 血脂異常症藥物
    • 抗高血壓藥物
  • 中樞神經系統
    • 抗憂鬱症
    • 抗癲癇藥物
    • 抗精神病藥物
  • 消化器官系統
    • 制酸劑
    • 瀉藥
  • 疼痛管理
    • 非鴉片類鎮痛藥
    • 鴉片類藥物

第9章：品牌學名藥市場：依應用領域分類

  • 動物用藥品
    • 伴侶動物
      • 貓
      • 狗
    • 家畜
  • 人類健康

第10章：品牌學名藥市場：依通路分類

  • 線上
  • 離線

第11章 品牌學名藥市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 品牌學名藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 品牌學名藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Apotex Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Limited
  • Endo International plc
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Krka, dd, Novo mesto
  • Lupin Limited
  • Mankind Pharma Limited
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sandoz Group AG
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • Viatris Inc.
  • Wockhardt Limited
  • Zydus Lifesciences Limited
Product Code: MRR-A26E0E57422E

The Branded Generics Market is projected to grow by USD 585.24 billion at a CAGR of 6.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 381.81 billion
Estimated Year [2026] USD 405.14 billion
Forecast Year [2032] USD 585.24 billion
CAGR (%) 6.29%

Branded generics are off-patent medicines sold under proprietary brand names, combining generic-drug cost advantages with brand-led trust, differentiated packaging, physician familiarity, and patient adherence support. In many markets, branded generic drugs occupy a critical position between innovator brands and unbranded generics, particularly where prescribing decisions are influenced by clinical confidence, pharmacy availability, perceived quality, and continuity of supply.

Demand is supported by patent expirations, aging populations, rising chronic disease prevalence, and payer pressure to reduce pharmaceutical expenditure. Verified public health sources, including the FDA and WHO, consistently show the central role of generic medicines in improving access and reducing medicine costs, while branded generics remain especially relevant in emerging markets where brand reputation, regulatory compliance, and quality assurance are strong purchase drivers.

Transformative Shifts in the Branded Generics Landscape

The branded generics landscape is shifting from volume-led expansion to evidence-backed, quality-focused competition. Governments are tightening price controls, expanding reference pricing, promoting generic substitution, and using centralized procurement to lower drug costs, forcing manufacturers to defend value through reliability, therapeutic breadth, and differentiated service models.

At the same time, supply chain resilience has become a board-level priority. Manufacturers are diversifying active pharmaceutical ingredient sourcing, investing in serialization and track-and-trace systems, and aligning with stricter good manufacturing practice expectations as regulators increase scrutiny of product quality, bioequivalence, pharmacovigilance, and medicine shortages.

Cumulative Impact of Artificial Intelligence in Branded Generics

Artificial intelligence is accelerating branded generics decision-making across portfolio selection, demand forecasting, manufacturing quality, regulatory intelligence, and safety monitoring. AI-enabled analytics can identify attractive loss-of-exclusivity opportunities, predict demand fluctuations, support inventory planning, and improve pharmacovigilance signal detection from structured and unstructured real-world data.

The impact is cumulative because each use case strengthens the next: better forecasting supports supply reliability, stronger quality analytics reduce batch deviations, and real-world evidence improves product positioning and post-market monitoring. Leaders must pair AI adoption with validated models, data lineage, cybersecurity controls, privacy compliance such as HIPAA or GDPR where applicable, and GxP-ready governance for regulated pharmaceutical operations.

Key Regional Insights for Branded Generics

Asia-Pacific remains a major growth engine for branded generics, supported by India and China manufacturing scale, Japan's pro-generic reimbursement policies, and expanding healthcare coverage across Southeast Asia. The region benefits from large patient populations, increasing chronic disease treatment needs, and policy efforts to improve access to affordable medicines, while regulators continue strengthening quality, bioequivalence, and pharmacovigilance expectations.

North America is shaped by FDA abbreviated approval pathways, high generic prescription utilization, payer formularies, state-level substitution rules, and competitive pharmacy benefit management dynamics. Latin America continues to expand through public-sector access programs and regulatory modernization in markets such as Brazil and Mexico, where medicine affordability and pharmacy-based access remain important drivers. Europe is defined by mature generic substitution policies, national reimbursement controls, and EMA-aligned quality expectations, with governments closely monitoring availability and medicine shortages. The Middle East is investing in localization, tender modernization, and medicine-security strategies, while Africa's opportunity is tied to essential medicine access, reduced import dependence, stronger national regulatory systems, and regional harmonization initiatives supported by public health authorities.

Key Group Insights Across Strategic Branded Generics Markets

ASEAN markets are becoming more attractive as regulatory convergence, health coverage expansion, and private pharmacy networks improve access to branded generics across diverse income and healthcare settings. The GCC is advancing localization, tender efficiency, and medicine-security strategies, creating opportunities for compliant manufacturers with regional partnerships, resilient supply chains, and consistent regulatory documentation.

The European Union emphasizes affordability, pharmacovigilance, quality assurance, and supply continuity through coordinated regulation and national pricing systems. BRICS economies combine large patient pools, rising noncommunicable disease burdens, and manufacturing depth, while also applying stronger regulatory oversight and procurement discipline. G7 markets reward high compliance, dependable supply, and evidence-supported differentiation despite sustained price pressure from payers and health technology assessment practices. NATO members increasingly view pharmaceutical supply resilience, essential medicine availability, and cross-border preparedness as part of broader health-security planning.

Key Country Insights for Priority Branded Generics Markets

The United States leads in generic utilization, supported by FDA regulation, payer formularies, and a deep retail pharmacy network, while Canada emphasizes public and private reimbursement discipline, provincial formulary management, and cost-effective access. Mexico and Brazil are expanding branded generic demand through large populations, chronic disease burdens, growing pharmacy channels, and evolving regulatory capacity focused on safety, quality, and bioequivalence.

The United Kingdom, Germany, France, Italy, and Spain maintain mature access systems where reimbursement, prescribing rules, reference pricing, and pharmacy substitution shape competition for branded generics. Russia remains driven by localization policy, public procurement, and essential medicine demand. China and India are pivotal for scale, active pharmaceutical ingredient supply, formulation manufacturing, and domestic access priorities, while China's volume-based procurement and India's quality-focused regulatory strengthening influence competitive behavior. Japan, Australia, and South Korea prioritize quality, aging-population demand, regulated reimbursement pathways, and stringent post-market expectations, making compliance and reliable supply central to branded generic success.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize branded generic portfolios around high-burden chronic diseases, proven bioequivalence, dependable supply, and markets with favorable loss-of-exclusivity timing. Commercial strategy should combine physician education, pharmacy engagement, patient adherence tools, and localized branding that communicates quality, access, and continuity without overstating clinical differentiation.

Executives should strengthen dual sourcing, regional manufacturing options, regulatory intelligence, shortage-risk monitoring, and real-world evidence generation. AI investments should start with validated use cases in demand planning, pharmacovigilance, regulatory surveillance, and quality assurance, supported by transparent governance, auditable data, cybersecurity controls, and clear accountability for regulatory compliance.

Research Methodology

This executive summary is built on a structured research methodology combining secondary research, regulatory review, policy assessment, market triangulation, and expert interpretation. Publicly verifiable sources include regulator guidance, national medicine agencies, WHO essential medicine frameworks, FDA and EMA resources, OECD health indicators, and published pharmaceutical policy and access literature from recognized public and institutional sources.

Findings are assessed through product, geography, regulatory, payer, prescribing, pharmacy, and supply chain lenses. Insights are validated by comparing policy direction, medicine utilization trends, patent-expiry dynamics, manufacturing capacity, quality requirements, pharmacovigilance expectations, and reimbursement behavior to identify durable branded generics opportunities rather than short-term market noise.

Conclusion

Branded generics remain central to global pharmaceutical access because they balance affordability, therapeutic familiarity, and brand-based confidence. Their relevance is increasing as health systems seek cost containment while patients, pharmacists, and prescribers continue to value dependable quality, availability, and continuity of treatment.

The next phase of branded generics competition will favor organizations that combine regulatory excellence, resilient supply chains, evidence-based commercialization, localized access strategies, and responsible AI adoption. Winners will not compete on price alone; they will build trusted, compliant, and regionally adaptive branded generic platforms that support sustainable medicine access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Branded Generics Market, by Dosage Form

  • 7.1. Injections
    • 7.1.1. Intramuscular
    • 7.1.2. Intravenous
    • 7.1.3. Subcutaneous
  • 7.2. Liquids
    • 7.2.1. Suspensions
    • 7.2.2. Syrups
  • 7.3. Tablets & Capsules
    • 7.3.1. Extended Release
    • 7.3.2. Immediate Release
  • 7.4. Topicals
    • 7.4.1. Creams
    • 7.4.2. Gels
    • 7.4.3. Ointments

8. Branded Generics Market, by Therapeutic Area

  • 8.1. Anti-Infectives
    • 8.1.1. Antibiotics
    • 8.1.2. Antifungals
    • 8.1.3. Antivirals
  • 8.2. Cardiovascular
    • 8.2.1. Anti-Dyslipidemics
    • 8.2.2. Anti-Hypertensives
  • 8.3. Central Nervous System
    • 8.3.1. Anti-Depressants
    • 8.3.2. Anti-Epileptics
    • 8.3.3. Anti-Psychotics
  • 8.4. Gastrointestinal
    • 8.4.1. Antacids
    • 8.4.2. Laxatives
  • 8.5. Pain Management
    • 8.5.1. Non-Opioid Analgesics
    • 8.5.2. Opioids

9. Branded Generics Market, by Application

  • 9.1. Animal Health
    • 9.1.1. Companion Animals
      • 9.1.1.1. Cats
      • 9.1.1.2. Dogs
    • 9.1.2. Livestock
  • 9.2. Human Health

10. Branded Generics Market, by Distribution Channel

  • 10.1. Online
  • 10.2. Offline

11. Branded Generics Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Branded Generics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Branded Generics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Alembic Pharmaceuticals Limited
  • 15.3. Alkem Laboratories Limited
  • 15.4. Apotex Inc.
  • 15.5. Aspen Pharmacare Holdings Limited
  • 15.6. Aurobindo Pharma Limited
  • 15.7. Bausch Health Companies Inc.
  • 15.8. Biocon Limited
  • 15.9. Cipla Limited
  • 15.10. Dr. Reddy's Laboratories Ltd.
  • 15.11. Emcure Pharmaceuticals Limited
  • 15.12. Endo International plc
  • 15.13. Fresenius Kabi AG
  • 15.14. Glenmark Pharmaceuticals Limited
  • 15.15. Hikma Pharmaceuticals PLC
  • 15.16. Jubilant Pharmova Limited
  • 15.17. Krka, d. d., Novo mesto
  • 15.18. Lupin Limited
  • 15.19. Mankind Pharma Limited
  • 15.20. Natco Pharma Limited
  • 15.21. Pfizer Inc.
  • 15.22. Sandoz Group AG
  • 15.23. Sanofi S.A.
  • 15.24. STADA Arzneimittel AG
  • 15.25. Sun Pharmaceutical Industries Ltd.
  • 15.26. Teva Pharmaceutical Industries Ltd.
  • 15.27. Torrent Pharmaceuticals Limited
  • 15.28. Viatris Inc.
  • 15.29. Wockhardt Limited
  • 15.30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRANDED GENERICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BRANDED GENERICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BRANDED GENERICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BRANDED GENERICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIQUIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIQUIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIQUIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TABLETS & CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TABLETS & CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TABLETS & CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EXTENDED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EXTENDED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EXTENDED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TOPICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TOPICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TOPICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-DYSLIPIDEMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-DYSLIPIDEMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-DYSLIPIDEMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-DEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-DEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-DEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-EPILEPTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-EPILEPTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-EPILEPTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-PSYCHOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-PSYCHOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-PSYCHOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTACIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LAXATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LAXATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LAXATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-OPIOID ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-OPIOID ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-OPIOID ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CATS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CATS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CATS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LIVESTOCK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVESTOCK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL LIVESTOCK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 246. GCC BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 247. GCC BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 248. GCC BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 249. GCC BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. G7 BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 287. G7 BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. NATO BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 312. NATO BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 313. NATO BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. NATO BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 315. NATO BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 350. MEXICO BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 351. MEXICO BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 352. MEXICO BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 353. MEXICO BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 354. MEXICO BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 355. MEXICO BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 356. MEXICO BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 357. MEXICO BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 358. MEXICO BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 359. MEXICO BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 360. MEXICO BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 361. MEXICO BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 362. MEXICO BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 363. MEXICO BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 364. MEXICO BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 365. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 366. BRAZIL BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 367. BRAZIL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 368. BRAZIL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 369. BRAZIL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 370. BRAZIL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 371. BRAZIL BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 372. BRAZIL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 373. BRAZIL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 374. BRAZIL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 375. BRAZIL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 376. BRA